Clinical Trials on RAD51D Gene Mutation in Switzerland

Total 26 results

iOMEDICO AG
Roche Pharma AG

Active, not recruiting

Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion (REALTRK)

NTRK Family Gene Mutation

Switzerland, Germany
ETOP IBCSG Partners Foundation
AstraZeneca

Active, not recruiting

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
University Hospital, Basel, Switzerland

Recruiting

Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial (LUMEN1)

MEN1 Gene Mutation

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Lung Cancer | KRAS Gene Mutation | Advanced Non-small Cell Lung Cancer

Switzerland
Martin Berli
Bern University of Applied Sciences

Completed

Sensor Glove and Non-Invasive Vibrotactile Feedback Insole to Improve Hand Prostheses Functions and Embodiment (FeetBack)

Amputation; Traumatic, Hand

Switzerland
University Hospital Inselspital, Berne
University of Zurich; University Hospital Muenster

Completed

Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women (CAG-Libido)

Polymorphism, Genetic | Libido | Receptors, Androgen | Androgen Effect

Switzerland
University of Zurich
ETH Zurich

Recruiting

CNS Changes Following Amputation

Amputation, Congenital | Upper Limb; Amelia

Switzerland
University Hospital, Basel, Switzerland

Completed

Clitoral Reconstruction (CR) in FGM/C Patients

Female Genital Mutilation / Cutting (FGM/C)

Switzerland
ETH Zurich

Recruiting

Enhancing Abilities in Amputees and Patients With Peripheral Neuropathy Through Restoration of Sensory Feedback

Lower Limb Amputation Below Knee (Injury) | Lower Limb Amputation Above Knee (Injury) | Diabetic Peripheral Neuropathy | Lower Limb Amputation Knee

Switzerland
University Hospital Inselspital, Berne
Swiss National Science Foundation

Recruiting

Metabolic Characterization of Space Occupying Lesions of the Brain (FASTMRSI)

Glioma | Brain Tumor | IDH Mutation

Switzerland
Rehaklinik Bellikon
Cort X Sensorics GmbH

Unknown

Descriptive Study of Receptive Fields in Lower Limb Amputees

Lower Limb Amputation Below Knee (Injury)

Switzerland
Kantonsspital Aarau

Completed

Clinical Trial Comparing Conventional and Robot-assisted(Da Vinci®)Laparoscopic Interventions for Hysterectomy

Postoperative Complications | Intraoperative Complications | Laparoscopic Technique no Switch to Open | Duration of Surgery

Switzerland
University of Lausanne Hospitals

Recruiting

Clinical Trial Comparing Negative Pressure Wound Therapy and Standard Dry Dressings (BERLYTZ)

Amputation | Arthroplasty Complications | Prosthesis-Related Infections

Switzerland
Blueprint Medicines Corporation

Completed

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

Systemic Mast Cell Activation | KIT D816V Mutation

United States, France, United Kingdom, Italy, Germany, Belgium, Spain, Switzerland
Pfizer

Completed

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Solid Tumors Harboring a BRAF V600 Mutation

United States, France, Italy, Singapore, Australia, Spain, Switzerland, Canada, Belgium
Novartis Pharmaceuticals

Completed

Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Chronic Myeloid Leukemia With T315I Mutation

Switzerland
Swiss Tropical & Public Health Institute

Completed

Effects of Ward Cats in Patients With Substance Abuse, Depression and Psychosis at UPK Basel

Satisfaction | Station Atmosphere

Switzerland
Bayer

Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

United States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
ETH Zurich
Neural Control of Movement laboratory ETH Zurich

Recruiting

multiSENSory Stimulation to tArgeT Sensory Loss and chronIc Pain in neurOpathic patieNts (SENSATION)

Diabetic Neuropathies | Amputation | Neuropathy | Neuropathy, Painful | Sensory Neuropathy

Switzerland
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
Basilea Pharmaceutica

Completed

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)

Intrahepatic Cholangiocarcinoma | Combined Hepatocellular and Cholangiocarcinoma

Canada, United States, Spain, Belgium, Italy, Korea, Republic of, Germany, Switzerland, France, United Kingdom, Ireland
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Spain, Switzerland, Germany, United States, Netherlands
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Kidney Tumors in Younger Patients

Renal Cell Carcinoma | Wilms Tumor | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Renal Cell Carcinoma Associated With Xp11.2 Translocations... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Israel, Switzerland

Clinical Trials on RAD51D Gene Mutation in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations